Explore the vast range of titles available.

This study aimed to assess menopause-specific quality of life among naturally postmenopausal women in Arar City, Saudi Arabia, and to examine its association with selected sociodemographic, reproductive, and health-related characteristics. A cross-sectional study was conducted among 377 naturally postmenopausal women aged 40 years or older recruited from primary health care centers in Arar City. Data were collected using a structured questionnaire that captured sociodemographic and health-related characteristics together with the 29-item Menopause-Specific Quality of Life (MENQOL) questionnaire. Descriptive statistics summarized the data, and chi-square or Fisher’s exact tests examined associations between categorized quality-of-life outcomes and participant characteristics. To complement the categorical analyses, MENQOL domain scores were also examined as continuous variables in a sensitivity analysis using independent-samples t-tests and one-way analysis of variance. Most participants were aged 46–65 years (85.1%), married (75.1%), and had secondary or university education (84.4%). Sexual symptoms were the most affected domain (81.5%), followed by physical (74.0%), psychological (72.7%), and vasomotor symptoms (71.9%). Poorer overall quality of life was significantly associated with marital status, parity, occupation, household income, body mass index, age at menarche, age at natural menopause, hypertension, diabetes mellitus, and negative perceptions of life after menopause (all p  < 0.05). Detailed frequencies and test statistics are presented in Tables 1, 2, 3, 4 and 5. Naturally postmenopausal women in this Saudi sample experienced a substantial menopausal symptom burden, particularly in the sexual, physical, and psychological domains. Several social and health-related factors were associated with poorer quality of life, supporting the need for culturally responsive nursing assessment, lifestyle counselling, and psychosocial support to enhance menopausal care and well-being.

To investigate the quality of life (QOL) of menopausal Emirati women aged 40–64 years and determine its relationship with their sociodemographic characteristics. A community-based cross-sectional study was conducted on 70 Emirati women using multistage stratified clustered random sampling. The participants were interviewed face-to-face using a structured questionnaire comprising sociodemographic variables, reproductive characteristics, and the Menopause-Specific Quality of Life (MENQOL) questionnaire. The most common symptom among the study participants was ‘aching in the muscles’. The participants had a moderate level of bothersome symptoms; in addition, vasomotor symptoms were reported by 61%, while sexual symptoms were only reported by one-third of the participants. There were no significant differences between the menopausal status in any of the four domains of the MENQOL questionnaire. Additionally, there were no significant differences between the mean scores of the four MENQOL domains and all predictors. This study highlights the importance of educating women about menopause and its symptoms.

Introductions For young premenopausal breast cancer patients, adjuvant chemotherapy may cause menstrual disruptions and premature menopause, which may in turn impair their quality of life (QoL). In this study among young breast cancer survivors who have undergone adjuvant chemotherapy, the objectives were to assess post-treatment menopausal symptoms and their associated factors, and to correlate these symptoms with breast cancer-specific QoL. Methods The study population included premenopausal young Chinese women with early-stage breast cancer who had undergone adjuvant chemotherapy between 3 and 10 years prior to enrolling into this study. At study entry, patients’ characteristics and clinical features were collected; each patient had detail menstrual history collected and each filled in MENQOL and FACT-B + 4 questionnaires. Results Two hundred eighty eligible patients were recruited. For adjuvant chemotherapy, 92% received anthracyclines and 28% received taxanes; 76% received adjuvant tamoxifen. At a median of 5.0 years from initial cancer diagnosis, 49 and 11% had become post- and peri-menopausal respectively. MENQOL at study entry revealed that physical domain score was worse in overweight/obese patients (mean scores for underweight/normal vs overweight/obese: 2.65 vs 2.97, p  = 0.0162). Vasomotor domain score was worse in those who received taxanes or tamoxifen (taxane vs non-taxane: 2.91 vs. 2.35, p  = 0.0140; tamoxifen vs no tamoxifen: 2.75 vs. 2.34, p  = 0.0479). Sexual domain score was worse among those who had become peri/post-menopausal (peri/postmenopausal vs premenopausal: 2.82 vs. 2.29, p  = 0.0229). On the other hand, patients who utilized traditional Chinese medicine had significantly worse scores for vasomotor, psychosocial and physical domains. Further, there was a significant association between MENQOL scores and FACT-B + 4 scores; less severe symptoms in the MENQOL domains were associated with better QoL scores in FACT-B + 4 physical, functional, psychosocial and emotional well-being, Breast Cancer Subscale, Arm Subscale and FACT-B total score. Conclusion Among premenopausal breast cancer women who had undergone adjuvant chemotherapy, those who had received taxanes or tamoxifen, were overweight/obese and utilized traditional Chinese medicine had more severe menopausal symptoms. Patients who experienced worse menopausal symptoms were found to have worse breast cancer-specific QoL. Interventional studies with an aim to alleviate menopausal symptoms are warranted to assess if overall QoL of these patients could be improved. Trial registration Not applicable.

To assess menopause specific Quality of life and its predictors among rural postmenopausal women in Jammu region of UT of J&K, India.Methodology: This community based cross- sectional study was conducted among 250 rural postmenopausal womenwho had attained natural menopause. During the review of literature, it was evident that, there is dearth of research among the postmenopausal women on many of these dimensions and their net impact on the women's quality of life especially in developing countries.In India, although, the health issues of women in the reproductive group are taken well care of via a wide network of dedicated health programs. Materials and Methods This cross sectional study was conducted in a rural healthblock RS Pura, attached as field practice area to the PostgraduateDepartment of Community Medicine GMC Jammu, J&K for teaching and training of undergraduates, interns and post-graduates. Considering a non-response rate of 10%, final sample size arrived at 240.

Background While there exist safe hormonal and non-hormonal therapeutic interventions for the menopause, their efficacy profiles are not fully characterized. This study sought to use a symptom checklist to examine menopausal symptom relief associated with different treatments. Methods An online survey study was conducted between December 2023 and February 2024. Convenience sampling was conducted, with participants recruited via social media, email, through relevant foundations and support groups, and by word-of-mouth. Inclusion criteria were: (1) ≥ 18 years, (2) assigned female at birth, (3) strong comprehension of the English language, and (4) must be currently experiencing symptoms of the menopause or menopause transition. 3330 respondents consented to participate in the study and of these, 91.95% ( N  = 3062) who had completed at least 88% of the survey were included in the analysis. Symptom relief per treatment (transdermal hormone replacement therapy (HRT), oral HRT, vaginal HRT, antidepressants, testosterone, cognitive behavioral therapy (CBT)/other therapy/counseling) was assessed using the symptoms included in the Menopause-Specific Quality of Life (MENQOL) questionnaire, which measures four symptom domains: vasomotor, psychosocial, physical, and sexual. Results Data from a total of 3062 respondents were included for analysis (mean age = 51.97, SD = 5.24). Treatment response rates differed significantly across the domains (vasomotor: F (5,2340) = 204.93, p  < 0.001, η 2  = 0.31; psychosocial: F (5,2340) = 75.12, p  < 0.001, η 2  = 0.14; physical: F (5,2340) = 65.46, p  < 0.001, η 2  = 0.12; sexual: F (5,2340) = 89.34, p  < 0.001, η 2  = 0.16). Transdermal HRT performed better at reducing vasomotor symptoms relative to all other treatment options. Regarding psychosocial symptoms, CBT/other therapy/counseling outperformed all other treatment options. The use of transdermal HRT and testosterone was associated with greater response rates in physical symptoms relative to other treatments. Finally, vaginal HRT and testosterone were associated with significantly higher response rates in sexual symptoms in comparison to all other treatments. Conclusions The findings demonstrate differential response rates to menopausal treatments across symptom domains, underscoring the importance of a comprehensive, multidimensional approach to menopausal symptom management. Utilizing a symptom checklist can facilitate the tailoring of treatment plans for specific symptom profiles and patient needs. The outcomes of this study hold considerable implications for improving and shaping treatment guidelines for the menopause.

Introduction Menopause, defined as the cessation of menstruation for at least 12 months, is one of the important stages of a woman's life cycle. Some hormonal variations occur during the transition to menopause, which affects women’s quality of life. Recently, the role of dietary factors in alleviating symptoms has been investigated. Aim of this study We tried to investigate the relationship between dietary inflammatory index (DII), food-based dietary inflammatory index (FDII) and quality of life, and menopausal symptoms, comparing their predictive power and suggesting the best cut-off point. Methodology One hundred forty-nine postmenopausal women were included in the cross-sectional study. After collecting data by interview, the desired variables were calculated. Logistic regression and ROC curves were used to investigate the relationship and predictive power of DII and FDII with menopausal symptoms. Findings We observed that both DII and FDII were significantly associated with the severity of sexual symptoms. The first tertile of DII (OR = 0.252, P -value = 0.002) and FDII (OR = 0.316, P -value = 0.014) had a significantly lower odds ratio for severe to moderate symptoms compared to the third tertile. Both inflammatory indices had significant predictive power in predicting the probability of having severe to moderate poor quality of life (FDII ( p -value = 0.004) > DII ( p -value = 0.006)) and sexual symptoms (DII ( p -value = 0.002) > FDII ( p -value = 0.003)). Also, regarding the physical subtype, only FDII ( p -value = 0.002) results were significant. Conclusion Both dietary inflammatory indices appear to be suitable for predicting quality of life, but FDII had slightly more predictive power. It seems that the quality of life and severity of menopausal symptoms may be improved, particularly with regard to sexual symptoms, by following an anti-inflammatory diet.

Although it looks reasonable to say menopausal women experience significant changes in quality of life, however the period is filled with anxiety and distress. Women can experience an array of symptoms including hot flushes, night sweats, sleep and mood disorders, impaired memory, lack of concentration, nervousness, depression, insomnia, bone and joint complaints Objectives:1. To assess Quality of life in menopausal women attending primary health care centers of Jazan, KSA 2. To conduct factor analysis for the variables affecting quality of life of menopausal women Methodology: A cross-sectional study conducted in primary health centers located in Jazan city. All menopausal women between age of 40-79 years were considered. A predesigned questionnaire drawn from World Health Organization Quality Of Life BREF (WHO QOL BREF) utilized Results: Mean age was 50.02+4.5 (Age + SD) Physical changes domain mean was 1.42+1.46 (mean + SD), greater than other domains and the participants were experiencing physical changes affecting quality of life more than any domain Sexual changes domain mean + SD was 1.21+1.99 and the participants were extremely bothered with symptoms of this domain. Conclusions: Significant shift in health care services is required for improving QOL of menopausal women which continue to be overlooked.

Background and Objectives: The aim of this study was to investigate lifestyle, menopausal symptoms, depression, post-traumatic stress disorder (PTSD) and sleep disorders in post-menopausal women throughout the first wave of the COVID-19 pandemic, including the impact of menopause hormonal therapy (HT). Materials and Methods: Post-menopausal women were given the following questionnaires: socio-demographic characteristics; lifestyle; history of COVID-19; menopause-specific quality of life (MENQOL), the first part of which refers to the pre-pandemic period (“pre COVID-19”) and the second refers to the current period (“during COVID-19”); Beck’s depression inventory (BDI); the impact of event scale-revised (IES-R); and the Pittsburgh sleep quality index (PSQI). Results: One hundred and twenty-six women completed all questionnaires, with a mean age of 55.5 ± 6.0 years. The mean menopause duration was 5.7 ± 5.6 years. Twenty-four women were taking HT. A significant mean weight gain, a reduction in physical activity (respectively p < 0.001) and worsened quality of romantic relationships (p = 0.001) were reported during the pandemic. Menopausal symptoms did not vary significantly throughout the pandemic; however, women taking menopausal HT had lower physical (p = 0.003) and sexual (p = 0.049) MENQOL domain scores, lower depressive symptoms (p = 0.039) and better romantic relationships (p = 0.008). Conclusions: The COVID-19 pandemic caused reduced physical activity, worsened food habits and weight gain in post-menopausal women. They also reported a high rate of severe–moderate PTSD and a negative influence on their romantic relationships. Menopausal HT seems to be a potential protective factor for sexual and physical status and for symptoms of depression.

Background Vasomotor symptoms (VMS; hot flashes) associated with menopause have significant impacts on health-related quality of life and are a leading cause for women seeking medical attention. Patient-reported outcome (PRO) instruments are commonly used to assess treatment benefit in VMS clinical trials and must demonstrate supportive evidence of measurement properties within the context of use. This study evaluated the measurement properties of scores from the Hot Flash Daily Diary (HFDD), PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) and Menopause-Specific Quality of Life (MENQOL) for measuring treatment efficacy in VMS clinical trials. Methods Measurement properties of the HFDD, PROMIS SD SF 8b, and MENQOL scores were assessed using data ( n  = 400 participants) from a randomized, placebo-controlled, phase 3 study evaluating the efficacy and safety of elinzanetant for the treatment of VMS in postmenopausal women (OASIS 2). Analyses assessed distributional properties, reliability, validity, responsiveness, and thresholds for meaningful change. Results Minimal floor and ceiling effects were found across the instruments at baseline. Inter-item correlations, and confirmatory factor analysis or item-response theory supported dimensionality and scoring for the MENQOL and PROMIS SD SF 8b, respectively. Test-retest reliability between Weeks 8 and 12 was good to excellent for HFDD Frequency and Severity of moderate-to-severe hot flashes scores, PROMIS SD SF 8b T-score and MENQOL Total score (intra-class correlation coefficients 0.835–0.971). Convergent and divergent correlations with instruments assessing similar or distinct constructs were consistent with pre-specified hypotheses. Known-groups validity was supported by significant differences ( p  < 0.0001) between subgroups hypothesized a priori as being clinically distinct. Responsiveness was indicated by consistent and statistically significant differences ( p  < 0.0001) in mean changes from baseline to Week 4 and 12 between groups of participants classified as ‘improved’, ‘stable’ and ‘worsened’ (effect sizes for improvement 0.81–4.62). Triangulation of estimates from multiple anchor-based analyses derived meaningful within-individual change thresholds for the HFDD, PROMIS SD SF 8b and MENQOL scores that were likely to exceed measurement error. Conclusions Findings provide evidence that HFDD, PROMIS SD SF 8b, and MENQOL scores are valid, reliable and responsive to change, supporting their use for assessing key efficacy endpoints in VMS clinical trials.

To assess the effect of low-dose combined oestradiol and norethindrone acetate hormone therapy (HT) on serum C-reactive protein (CRP) levels and life quality in natural menopause women. Forty-five natural menopause women admitted to the clinic during a 1-year period and diagnosed as menopause, who planned to have HT for menopausal symptoms, were enrolled in this prospective study. The serum CRP levels were measured, and vasomotor symptoms scores were graded according to the Blatt-Kupperman menopause index, and life quality scores according to the Menopause-Specific Quality of Life Questionnaire (MENQOL) were recorded before and after (3 months later) hormone therapy. The Blatt-Kupperman menopause index and MENQOL scores were significantly decreased after 3 months of low-dose treatment. No significant difference was found between white blood cell counts and serum CRP levels before and after 3 months of hormone therapy. Considering all HT types and biochemical effects, low-dose HT, which had positive results in terms of quality of life, was a safe treatment and could be preferred to conventional-dose preparations in cases without contraindications. Low-dose combined HT containing oestradiol and norethindrone acetate did not alter the serum CRP level in postmenopausal cases.